Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 2(3)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02200718Phase 1Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Role: lead

NCT02057159Phase 2Unknown

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Role: lead

NCT02149706Phase 2Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Role: lead

NCT02291809Phase 2Unknown

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

Role: lead

NCT02366026Phase 3Unknown

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

Role: lead

All 5 trials loaded